Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | LTA4H | P09960 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3314498 | 1.00 | GAA (0.77) | GAAALDH1A1KDM4EHPGDCYP2D6 | |
| SCHEMBL6286609 | 0.91 | GAA (0.63) | GAAALDH1A1KDM4EHPGDLTA4H | |
| SCHEMBL2450749 | 0.91 | GAA (0.63) | GAAALDH1A1KDM4EHPGDLTA4H | |
| SCHEMBL6284121 | 0.91 | GAA (0.63) | GAAALDH1A1KDM4EHPGDLTA4H | |
| SCHEMBL18125935 | 0.88 | ALDH1A1 (0.71) | GAAALDH1A1KDM4EHPGDCYP2D6 | |
| SCHEMBL3844177 | 0.88 | ALDH1A1 (0.71) | GAAALDH1A1KDM4EHPGDCYP2D6 | |
| SCHEMBL8318203 | 0.88 | GAA (0.58) | GAAALDH1A1KDM4EHPGDCYP2D6 | |
| SCHEMBL27948458 | 0.87 | GAA (0.80) | GAAALDH1A1KDM4EHPGDCYP2D6 | |
| SCHEMBL4840777 | 0.87 | GAA (1.00) | GAAALDH1A1KDM4EHPGDLTA4H | |
| SCHEMBL3063205 | 0.87 | KDM4E (0.69) | GAAALDH1A1KDM4EHPGDCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2123769-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | KANEKA CORP (JP) | 2016-05-18 | — | — | EP | claimed |
| US-8338142-B2 | Method for producing optically active 3-aminopiperidine or salt thereof | KANEKA CORPORATION (JP) | 2012-12-25 | — | — | US | claimed |
| EP-2362775-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline LLC (US) | 2011-09-07 | — | — | EP | claimed |
| US-20100105917-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | KANEKA CORPORATION (JP) | 2010-04-29 | — | — | US | claimed |
| EP-3962485-A1 | SUBSTITUTED (PIPERIDIN-1-YL)ARYL ANALOGUES FOR MODULATING AVILACTIVITY | University Of Virginia Patent Foundation (US) | 2022-03-09 | — | — | EP | disclosed |
| WO-2020223715-A1 | SUBSTITUTED (PIPERIDIN-1-YL)ARYL ANALOGUES FOR MODULATING AVILACTIVITY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-11-05 | — | — | WO | disclosed |
| US-9783796-B2 | Amidase, gene for the same, vector, transformant, and method for production of optically active carboxylic acid amide and optically active carboxylic acid by using any one of those items | KANEKA CORPORATION (JP) | 2017-10-10 | — | — | US | disclosed |
| EP-2123769-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | KANEKA CORP (JP) | 2016-05-18 | — | — | EP | disclosed |
| EP-2123769-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | KANEKA CORP (JP) | 2016-05-18 | — | — | EP | disclosed |
| US-20150166481-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | KANEKA CORPORATION (JP) | 2015-06-18 | — | — | US | disclosed |
| US-20150166481-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | KANEKA CORPORATION (JP) | 2015-06-18 | — | — | US | disclosed |
| US-20150166481-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | KANEKA CORPORATION (JP) | 2015-06-18 | — | — | US | disclosed |
| EP-2362775-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline LLC (US) | 2011-09-07 | — | — | EP | disclosed |
| WO-2010059658-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-05-27 | — | — | WO | disclosed |
| US-20100105917-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | KANEKA CORPORATION (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100105917-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | KANEKA CORPORATION (JP) | 2010-04-29 | — | — | US | disclosed |
| EP-2128258-A1 | NOVEL AMIDASE, GENE FOR THE SAME, VECTOR, TRANSFORMANT, AND METHOD FOR PRODUCTION OF OPTICALLY ACTIVE CARBOXYLIC ACID AMIDE AND OPTICALLY ACTIVE CARBOXYLIC ACID BY USING ANY ONE OF THOSE ITEMS | Kaneka Corporation (JP) | 2009-12-02 | — | — | EP | disclosed |
| EP-2123769-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | Kaneka Corporation (JP) | 2009-11-25 | — | — | EP | disclosed |
| WO-2004002483-A1 | SUBSTITUTED 3- AND 4- AMINOMETHYLPIPERIDINES FOR USE AS BETA-SECRETASE IN THE TREATMENT OF ALZHEIMER’S DISEASE | ACTELION PHARMACEUTICALS LTD (CH) | 2004-01-08 | — | — | WO | disclosed |
| US-6664271-B1 | Amide, carbamate and uredo derivatives of 3-piperidine-carboxylic acid or ester; protecting against infection by such as escherichia coli and/or actinobacillus pleuropneumoniae | ELI LILLY AND COMPANY | 2003-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105917-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | NPEPPS, APEH, DNPEP | GAA 131/4885ALDH1A1 1293/4885KDM4E 1166/4885 |
| US-20150166481-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | NPEPPS, APEH, DNPEP | GAA 131/4885ALDH1A1 1293/4885KDM4E 1166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.